HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists

Not Applicable

Completed

• Conditions: COVID

• Registration Number: NCT04389294
• Lead Sponsor: Hospital for Special Surgery, New York

Brief Summary

The goal of this study is to understand the infectious exposure of SARS-coronavirus 2 (SARS-CoV2) among surgeons and anesthesiologists and to correlate this status with self-reported indices of COVID-19 illness.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-05-05
• Study First Submitted: 2020-05-08
• Study First Submitted QC: 2020-05-13
• Study First Posted: 2020-05-15
• Primary Completion: 2020-06-16
• Study Completion: 2020-09-04
• Results First Submitted: 2022-03-29
• Status Verified: 2023-03
• Results First Submitted QC: 2023-03-21
• Last Update Submitted: 2023-03-21
• Results First Posted: 2024-01-03
• Last Update Posted: 2024-01-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 143

Inclusion Criteria

• Accredited to practice at HSS
• All anesthesiology and surgery faculty
• All anesthesia and orthopedic surgery fellows
• All orthopedic surgery residents

Exclusion Criteria

• Refusal to participate in either of the interventions at either of the timepoints of interest

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Number of Participants With SARS-CoV-2 IgG Antibodies	Serology Test #1 (Study Enrollment) and Test #2 (3 months apart)	Prevalence of SARS-CoV-2 IgG antibodies by serology testing in participants at the time of study enrollment or 3 months later

Secondary Outcome Measures

Name	Time	Method
Number of Asymptomatic Participants With Positive Antibody Serology	Serology Test #1 (Study Enrollment) and Serology Test #2 (3 months apart)	Number of asymptomatic participants with positive antibody serology at either the study enrollment timepoint or 3 month timepoint
Percentage of Antibody-positive Participants Who Subsequently Develop COVID-19	Serology Test #1 (Study Enrollment) and Serology Test #2 (3 months apart)	Percentage of antibody-positive participants who subsequently develop COVID-19 at either the study enrollment timepoint or the 3 months time point
Differences in Sex Between IgG Antibody-positive vs. Negative Participants	Survey completed before or on day of serology testing asking about information from January 1, 2020 to May 5, 2020	Secondary outcomes included differences in the survey responses between IgG antibody-positive and -negative participants. These included demographics such as sex.
Differences in Race Between IgG Antibody-positive vs. Negative Participants	Survey completed before or on day of serology testing asking about information from January 1, 2020 to May 5, 2020	Secondary outcomes included differences in the survey responses between IgG antibody-positive and -negative participants. These included demographics such as race.
Differences in Comorbidities Between IgG Antibody-positive vs. Negative Participants	Survey completed before or on day of serology testing asking about information from January 1, 2020 to May 5, 2020	Secondary outcomes included differences in the survey responses between IgG antibody-positive and -negative participants. These included comorbidities.
Differences in Average Number of Adults in Household Between IgG Antibody-positive vs. Negative Participants	Survey completed before or on day of serology testing asking about information from January 1, 2020 to May 5, 2020	Secondary outcomes included differences in the survey responses between IgG antibody-positive and -negative participants. These included demographics such as number of adult household members.

Trial Locations

Locations (1)

Hospital for Special Surgery; 🇺🇸 New York, New York, United States